U.S. Stock Futures Plummet in Sympathy with China and Oil

Wall Street was limping into another open, holding on to heavy losses as more bad news from China triggered a selling spree in oil and global equity markets. After data showing that Chinese foreign exchange reserves fell by a record amount in December, Beijing orchestrated a 0.5% devaluation in the beleaguered yuan, setting in motion a swoon in Chinese equities that was quickly exported overseas. In less than 15 minutes of trade, the Shanghai plummeted more than 7%, permeating Europe and the U.S. where Dow futures were already more than 300 points below fair value.

Commodities were also taking it on the chin with oil at a 12-year low of $32.10, copper nearly 3% lower and struggling to hold onto a $2 handle, and nickel and zinc nearly 4% in the red. Precious metals are higher on their safe-haven status with gold trading $11 higher, and silver up $0.12.

Thursday's major piece of economic data was eclipsed by events overseas with a 10,000 decline in initial jobless claims for the week ended Jan 2 to 277,000 barely registering a response from Wall Street. On Friday, the Labor Department will release the pivotal non-farm payroll report for December.

-Dow Jones Industrial down 2.13%

-S&P 500 futures down 2.14%

-Nasdaq 100 futures down 2.73%


Nikkei down 2.33%

Hang Seng down 3.09%

Shanghai Composite down 7.32%

FTSE-100 down 2.93%

DAX-30 down 3.51%


(-) Large cap tech: Lower

(-) Chip stocks: Lower

(-) Software stocks: Lower

(-) Hardware stocks: Lower

(-) Internet stocks: Lower

(-) Drug stocks: Lower

(-) Financial stocks: Lower

(-) Retail stocks: Lower

(-) Industrial stocks: Lower

(-) Airlines: Lower

(-) Autos: Lower


(+) ZUMZ (+11.07%) Raised Q4 guidance

(+) QURE (+9.39%) Reported preliminary topline results from haemophilia B therapy clinical trial

(+) EZCH (+2.85%) Raging Capital Management, EZ Chip's largest shareholder, expressed support for merger with Mellanox ( MLNX )


(-) CLBS (-29.24%) Plans to discontinue Phase 3 study of CLBS20 for metastatic melanoma

(-) EPZM (-20.62%) Priced a 13.33 million share offering at $9 per share, a 22% discount to Wednesday's closing price

(-) FINL (-16.76%) Miss Q3 revenue estimates and lowered Q4 guidance

(-) AKBA (-11.46%) Priced 7.25 million share offering at $9 per share

(-) ATML (-7.23%) Micochip Technology ( MCHP ) was reconsidering its $9.00 per share offer

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.